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Abstract
After inheritance of chromosomally integrated HHV-6 (ciHHV-6), viral DNA is found in every nucleated cell. The prevalence of ciHHV-6 is
estimated to be 0.2–5% of humans. There are conﬂicting data on the potential for replication, possibly leading to clinical implications. We
analysed peripheral blood mononuclear cells (PBMCs) from individuals with ciHHV-6 proven by ﬂuorescence in situ hybridization (FISH) for
HHV-6-speciﬁc mRNA (U94, U42, U22) and antigens by means of reverse transcription PCR and an indirect immunoperoxidase staining.
U94 transcripts indicative of latent infection were detected in six (54.5%) out of 11 individuals at least once. Transcripts indicative of lytic
infection (i.e. U42 and U22) were detected in four (36.4%) out of 11 individuals at least once. HHV-6 antigen was detected in seven (70%)
out of 10 individuals at least once. The presence of viral mRNA and proteins supports virus gene expression from ciHHV-6, which may lead
to virus replication. Considering the properties of active HHV-6 infection together with obvious replicative activity in individuals with
ciHHV-6, pathophysiological effects leading to clinical consequences of chromosomally integrated viral DNA might be considered.
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Preliminary data on antigen detection in four of the reported patients
were selected for oral presentation at the 19th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID), which was
held in Helsinki in May 2009. Preliminary data on antigen detection
and mRNA detection have been presented at the 7th International
HHV-6 Conference (2011, Reston, USA) and 8th International HHV-6
Conference (2013, Paris, France). The manuscript containing com-
plete data on antigen detection and mRNA has neither been
presented nor submitted or accepted for publication elsewhere.
Introduction
Like other herpesviruses, HHV-6A and HHV-6B persist in the
host after primary infection [1,2]. This persistence comprises a
true latent state without replication and a low-level chronic
replication occurring at the same time in different cell types.
While latency is typically seen in peripheral blood mononu-
clear cells (PBMCs) and bone marrow progenitor cells, chronic
replication at a low level is attributed to the salivary glands
contributing to viral shedding [1]. Furthermore, HHV-6 can be
reactivated by a variety of mechanisms (e.g. other infections,
endotoxins, endocrine stimulation, certain cytokines and
immune deﬁciency) leading to lytic infection [1,2]. In addition,
chromosomal integration of HHV-6 DNA (ciHHV-6) into the
human genome is described in individuals with different
diseases (meningitis, encephalitis, myocarditis, convulsions,
liver dysfunction, haemolytic and aplastic anaemia, various
lymphomas and multiple sclerosis) for both species (HHV-6A
and HHV-6B) [3–10]. However, ciHHV-6 is also found in
healthy individuals [3]. It is inherited, and its prevalence is
estimated to be 0.2–5% [3]. It might be speculated that the high
expression of the HHV-6 receptor CD46 on the inner
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acrosomal membrane of spermatozoa [11], leading to a high
afﬁnity of HHV-6 to spermatozoa [12], might facilitate
chromosomal integration into germ line cells and therefore
its inheritance.
After stem cell transplantation (SCT) from a donor with
ciHHV-6, ciHHV-6 is found in the recipient in every cell
derived from haematological stem cells [10].
CiHHV-6 results in persistently high levels of HHV-6 DNA
in blood and tissue, which might be interpreted as persistent
active HHV-6 infection [5,7,8,10]. Up to now, it is unclear
whether there is transcription of the integrated DNA,
translation into viral proteins or even full replication of viral
particles [3]. Hence, the clinical consequences of ciHHV-6
remain unclear [3,8].
We investigated 12 individuals out of six families with
proven ciHHV-6 for the presence of HHV-6-speciﬁc mRNA
and antigens, which both have been shown to be able to
discriminate active infection from latency.
Methods
Clinical samples
Twelve individuals with suspected ciHHV-6 (six patients and
six relatives) were analysed. One of these individuals had
become HHV-6 DNA positive after SCT [10]. CiHHV-6
was proven by ﬂuorescence in situ hybridization (FISH) in
all 12 individuals, as described elsewhere [13]. HHV-6A and
HHV-6B were differentiated by a nested PCR, resulting in
different sized amplicons for HHV-6A and HHV-6B [14]. In
the seven persons who were repeatedly tested for mRNA
and/or antigen expression, the mean interval between blood
drawings was 5.3 (1.6–11.3) months.
mRNA Analyses
HHV-6 transcriptional activity was analysed by nested
qualitative PCR and real-time quantitative PCR (qPCR) after
retrotranscription (RT-PCR, RT-qPCR), determining the
presence of lytic (U42, U22) or latent (U94 in the absence
of U42) mRNAs, as previously reported [15]. Brieﬂy, total
RNA was extracted from cell pellets by the RNA Easy
isolation kit (Qiagen, Hilden, Germany), according to man-
ufacturer’s instructions, and DNA contamination was elimi-
nated by digestion with RNase-free DNase (Roche Rotkreuz,
Risch, Switzerland). After reverse transcription using AMV
reverse transcriptase (Ambion Inc., Austin, TX, USA), PCR
ampliﬁcations were performed using an amount of cDNA
corresponding to 200 ng of total RNA. All RNA preparations
were devoid of DNA, as assured by multiple DNase
digestions and lack of ampliﬁcation in PCR reactions where
retrotranscription had been omitted [16]. Ampliﬁcations of
the house-keeping human b-actin and RNase P genes were
used as controls, respectively, in qualitative and quantitative
PCR ampliﬁcations. qPCR reactions were carried out in
triplicate on a 7500 PCR System (Applied Biosystems, Foster
City, CA, USA), as already described [15,17]. In each assay
the cDNAs obtained from uninfected and HHV-6-infected
JJhan T cells were also included as negative and positive
controls, respectively. All clinical samples were analysed in a
randomized and blinded fashion. Qualitative PCR ampliﬁca-
tion products were visualized on ethidium bromide-stained
agarose gel after electrophoresis migration.
Antigen analyses
For the HHV-6 antigen test, PBMCs were acetone ﬁxed on
microscope slides and stored at 70°C. HHV-6 antigens were
demonstrated in PBMCs by means of an indirect immunoper-
oxidase staining as described elsewhere [18]. Two monoclonal
antibodies were used: an antibody against a 101 kDa virion
protein of HHV-6B (MAB 8535; Chemicon, Inc., Temecula,
CA, USA) [19], which is a late antigen, usually not expressed in
the absence of virus replication [20], and an antibody
recognizing both HHV-6A and HHV-6B (Ref-11-242, Argene
Biosoft, Varilhes, France). This latter antibody detects a
70 kDa protein of HHV-6A and a 62 kDa protein of HHV-6B.
A peroxidase-conjugated rabbit anti-mouse (Dako, Copenha-
gen, Denmark) and peroxidase-conjugated goat anti-rabbit
antibody (Zymed, San Francisco, CA, USA) were used as
second and third antibody. Positive and negative control
specimens were included in every series of immunostaining.
The reaction was revealed by 3-amino-9-ethyl carbazole
solution containing hydrogen peroxidase; Mayer’s hemalum
was used for counterstaining.
Ethics statement
The study has been approved by the ethics committee of the
Medical University Graz. Participants or their caregivers have
provided written informed consent.
Results
mRNA analyses
Out of 27 samples analysed for HHV-6-speciﬁc mRNA, nine
(33.3%), ﬁve (18.5%) and one (3.7%) samples were positive for
U94, U42 and U22 transcripts, respectively (Fig. 1, Table 1).
U94 transcripts indicative of latent infection were detected in
six (54.5%) out of 11 individuals at least once. Transcripts
indicative of lytic infection (i.e. U42 and U22) were detected in
four (36.4%) out of 11 individuals at least once (Table 1).
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Antigen analyses
Virus antigen expression was detected in 12 out of 16 samples
(75%) (Figs 2 and 3, Table 1). Positivity for one or both of the
tested HHV-6 antigens was detected in seven out of 10
individuals with ciHHV-6 (70%) at least once. Six individuals
refused further blood drawings and were tested only once.
Interestingly, we found HHV-6B antigen in one individual with
integrated HHV-6A (individual no. 10). The amount of cells
positive for HHV-6B was much lower than that positive with
the anti-HHV-6A+B antibody (Fig. 3). The signal achieved with
the anti-HHV-6B antibody resembles the picture seen in
HHV-6 reactivation under immunosuppression [18,21–23].
TABLE 1. Results of mRNA and antigen detection in 12 individuals with proven ciHHV-6
Family (virus)
chromo-somal site Individual, clinical details
Year of
birth Sex Drawing
Nested PCR/qPCR
Antigen detection
U94 U42 U22
Antibodies useda
(proportion of positive cells)
A
(HHV-6B)
17p ter
1
transient arterial hypertension
with RPLE
1998 M a    AB (0%), B (0%)
2
healthy, mother of no. 1
1965 F a    B (15%)
B
(HHV-6B)
9p ter
3
psychogenic seizure
1992 F a    B (20%)
4
healthy, grandfather of no. 3
1948 M a +b   AB (10%), B (20%)
b +b   AB (10%), B (20%)
c    n.d.
5
healthy, father of no. 3
1968 M a +b   B (20%)
b    AB (10%), B (10%)
c +   AB (40%), B (40%) Fig. 1
d  +b  n.d.
C
(HHV-6A)
17p ter
6
AML, ciHHV-6 via SCT
1993 F a +b   AB (10%), B (0%)
b +   n.d.
D
(HHV-6B)
9p ter
7
CMP, unclear aetiology
2003 F a n.d. n.d. n.d. B (0%)
8
healthy, father of no. 7
1965 M a  +b  B (0%)
E
(HHV-6A)
17p ter
9
healthy, mother of no. 10
1964 F a + + + AB (0%)
b  +  AB (15%), B (0%)
c    n.d.
10
chronic parotitis, unclear
aetiology
1990 F a    AB (60%)
b    AB (60%)
c +   AB (60%), B (10%) Fig. 2
d    n.d.
e    n.d.
F
(HHV-6A)
11
healthy, father of no. 12
1960 M a   
12
Hodgkin disease
1993 F a +   n.d.
b  +  n.d.
c    n.d.
d    n.d.
e    n.d.
AML, acute myeloid leukaemia; SCT, stem cell transplantation; CMP, cardiomyopathy; RPLE, reversible posterior leukoencephalopathy syndrome; n.d., not done.
aAntibodies used: B, against HHV-6B (101p); AB, against HHV-6 A and B (see text).
bSamples had a positive result only in nested qPCR.
b C- 1a     2a    3a     4a    4b    4c   5a   5b    5c   5d    6a   6b    8a   9a   9b   9c  10a  10b  10c  10d  10e 11a 12a 12b  12c 12d 12e C+ MW
U94
U42
U22
FIG. 1. Results of HHV-6 mRNA search by nested qualitative PCR. PCR ampliﬁcations were performed using an amount of cDNA corresponding
to 200 ng of total RNA, using primers and conditions speciﬁc for genes U94, U42 and U22 of HHV-6. The cDNAs obtained from uninfected or
infected JJhan T cells were also included as negative (C) and positive (C+) controls. PCR products were visualized on ethidium bromide-stained
agarose gel after electrophoresis migration. Note: Some specimens had a positive result only in nested qPCR. For details see Table 1.
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This indicates exogenous infection or reactivation of HHV-6B
in this individual with ciHHV-6A.
Interestingly, HHV-6 speciﬁc antigens were found in spec-
imens without detectable HHV-6-speciﬁc mRNA and vice
versa (Table 1).
Discussion
For the ﬁrst time, we analysed HHV-6-speciﬁc mRNA as well
as antigens in a series of persons with FISH-proven ciHHV-6.
Both were detected in the majority of participants indicating
intermittent replication of HHV-6. While U94 transcripts can
also be detected in latently infected persons, U22 and U42
transcripts are indicative for lytic infections and are only
detected during exogenous primary infection or reactivation
but not in latently infected individuals [15–17]. In our series,
mRNA transcripts indicative for lytic infection were detected
in four of 11 tested persons.
The antibodies we used for antigen detection have been
shown to be sensitive and speciﬁc for HHV-6 antigens
indicating primary infection with or reactivation of HHV-6.
These antibodies are successfully used in monitoring of
patients after solid organ transplantation and SCT and their
target antigens are not detectable in latently infected persons
without reactivation [18,21–23].
In the current study, HHV-6 mRNAs and antigens were
detected in most of the individuals with ciHHV-6. However,
they were not detectable in all and at every time-point of
testing. Positive as well as negative samples were found within
the same families, within individuals with the same site of
integration, in individuals with integrated HHV-6A or HHV-6B
and even within the same individual at different time-points of
sampling. This may indicate a differential viral activity within a
time course of the same individual. Chlamydia trachomatis
infections as well as different drugs have been shown to be able
to trigger HHV-6 reactivation [8,24]. Exogenous factors might
play a role even in activation of ciHHV-6.
FIG. 2. HHV-6-positive lymphocytes in the cytocentrifuge preparations of peripheral blood mononuclear cells (PBMCs) of individual no. 5. (a)
HHV-6-positive cells demonstrated by indirect immunoperoxidase staining with the monoclonal antibody against HHV-6A and -B types (Ref-11-242;
Argene Biosoft). (Original magniﬁcation 9400.) (b) HHV-6B-positive cells (arrows) demonstrated by the monoclonal antibody against the B type
(MAB 8535, Chemicon, Inc.). Again c. 40% of PBMCs are positive for HHV-6B in this preparation (Original magniﬁcation 91000.)
FIG. 3. HHV-6-positive lymphocytes in the cytocentrifuge preparations of peripheral blood mononuclear cells (PBMCs) of individual no. 10. (a)
HHV-6-positive cells (arrows) demonstrated by indirect immunoperoxidase staining with the monoclonal antibody against HHV-6A and HHV-6B
(Ref-11-242, Argene Biosoft). c. 60% of PBMCs are positive with this antibody. (Original magniﬁcation 91000.) (b) indirect immunoperoxidase
staining with the monoclonal antibody against HHV-6B (MAB 8535, Chemicon, Inc.), c. 10% of the PBMC are expressing the HHV-6B protein (arrow).
(Original magniﬁcation 9400.)
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The lack of concordance between mRNA and antigen
detection in some specimens can be explained by the different
dynamics and biological half-life of the analysed parameters.
While mRNA is detectable for only a few days after infection
[17], HHV-6-speciﬁc antigens have been shown to be detect-
able for several weeks to months [25].
In addition, because U94 mRNA is commonly detected
during viral latency, but only intermittently and at low amounts
in individuals with ciHHV-6, it might be postulated that the
molecular mechanism underlying inherited ciHHV-6 and
latency after primary exogenous infection are considerably
different.
In the literature, there are conﬂicting data on the possible
viral replication in individuals with ciHHV-6. While culturing
HHV-6 from specimens of individuals with ciHHV-6 has not
succeeded [3], in vitro experiments have shown the capability
of cells with ciHHV-6A [26] or ciHHV-6B [27] to infect other
cells, clearly indicating the replicative potential of ciHHV-6 at
least in vitro. Hall et al. reported transient DNA detection in
blood and saliva of two unrelated newborns without ciHHV-6
born to mothers with ciHHV-6. DNA sequences of maternal
ciHHV-6 and of DNA detected in the ciHHV-6-negative
neonates were identical. Beside maternal microchimerism
(caused by small amounts of maternal DNA crossing the
placenta), replication of maternal ciHHV-6 as a source of
congenital infection might be an explanation for this observa-
tion [28,29]. On the other hand, Pantry et al. [30] demon-
strated HHV-6-speciﬁc mRNA of four patients with ciHHV-6
and chronic fatigue syndrome (CFS) with differences in the
nucleotide sequences between the integrated and the tran-
scribed DNA, indicating an exogenous infection as the source
of replication.
While our study comprises the largest series of individuals
with ciHHV-6 (most of them without speciﬁc symptoms)
reporting mRNA expression and the ﬁrst report of in vivo
antigen detection, our data do not, of course, allow
distinguishing reactivation of endogenous ciHHV-6 from
exogeneous super-infection. If our observations reﬂect lytic
infections/reactivations not derived from the chromosomally
integrated virus DNA, this might indicate that individuals with
ciHHV-6 are prone to exogenous HHV-6 re-infection or
reactivation, as proposed by Pantry et al. [30]. This hypoth-
esis is further substantiated by our observation of a
documented infection with or re-activation of HHV-6B in a
person with integrated HHV-6A. Of course, this is specula-
tive and the origin of viral transcripts and antigens in
individuals with ciHHV-6 should be determined in further
studies of larger numbers of individuals with and without
symptoms to clarify this aspect (actually, the effects may not
be different at all).
The presence of markers speciﬁc for lytic infection as well
as of viral antigens may tempt speculation regarding possible
pathophysiological effects leading to clinical consequences of
chromosomally integrated viral DNA. It might be speculated
that intermittent or permanent replication of viral structures
alters the immune response to an additional exogenous
infection with HHV-6 [8]. This might lead to a decreased
response with subclinical courses or with difﬁculties in
clearing the virus in individuals with ciHHV-6, leading to
severe and/or protracted courses. The observed replication
might also reﬂect the consequences of an altered immune
status.
In individuals without ciHHV-6, HHV-6 wild-type infection
and persistent activity has been reported to be associated with
different types of diseases such as malignant lymphomas,
encephalitis, multiple sclerosis, brain tumours, myocarditis,
Hashimoto0s thyroiditis, hepatitis and collagen vascular dis-
eases [1,2,15]. In vitro studies have shown that HHV-6
enhances the replication of EBV, HPV and HIV, inﬂuences
the activity of interferons, interleukins, TNF-alpha and differ-
ent cytokine receptors and activates NF-KB [1]. Furthermore,
expression of HLA class I and II molecules and of CD46 was
seen to be altered by HHV-6. The proliferative response of
stimulated T cells was shown to be markedly reduced after
HHV-6 infection [1], indicating an HHV-6-induced immune
suppression. HHV-6 was also reported to induce apoptosis of
CD4+ lymphocytes [1].
Considering all these properties of active HHV-6 infection
together with obvious replicative activity in individuals with
ciHHV-6 observed in our study, a pathophysiological impact of
this phenomenon might be assumed, irrespective of the origin
of the transcripts (replicated ciHHV-6 or persistent exogenous
super-infection). Furthermore, if replication occurs frequently
in persons with ciHHV-6, it might serve as a (permanent)
source of infection.
Our results demonstrate the presence of HHV-6-speciﬁc
mRNA and proteins in individuals with ciHHV-6. This indicates
virus gene expression and translation in individuals with
ciHHV-6, which may lead to virus replication. Especially in
individuals expressing U42/U22 mRNA and p101 protein,
there is evidence of virus replication because U42/U22
transcription is only detected in lytic infection [17] and p101
is a late gene whose expression is dependent on virus
replication [19,20].
So far, ciHHV-6 is not linked to speciﬁc clinical conditions
but, based on the evidence of HHV-6 transcriptional activity, a
possible clinical impact might be considered. Epidemiological
and detailed clinical-molecular studies are needed with a large
number of individuals with ciHHV-6 to identify the implications
and clinical consequence of this phenomenon.
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